Latest Update: Impact of current COVID-19 situation has been considered in this report while making the analysis.
Global Colorectal Cancer Drugs Market by Type (Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators, ), By Application (Radiotherapy, Chemotherapy, ) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030-report

Global Colorectal Cancer Drugs Market by Type (Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators, ), By Application (Radiotherapy, Chemotherapy, ) And By Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast From 2022 To 2030

Report ID: 171094 3300 Pharma & Healthcare 377 233 Pages 4.8 (38)
                                          

Industry Growth Insights published a new data on “Colorectal Cancer Drugs Market”. The research report is titled “Colorectal Cancer Drugs Market research by Types (Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators, ), By Applications (Radiotherapy, Chemotherapy, ), By Players/Companies AB Science, Amgen, Array BioPharma, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Elli Lilly, Roch, Hutchison MediPharma, Merck & Co., Inc., Mologen, Regeneron, Sanofi, Sumitomo Dainippon, Taiho Pharmaceutical, Vaccinogen”.

Scope Of The Report

Report Attributes

Report Details

Report Title

Colorectal Cancer Drugs Market Research Report

By Type

Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators,

By Application

Radiotherapy, Chemotherapy,

By Companies

AB Science, Amgen, Array BioPharma, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Elli Lilly, Roch, Hutchison MediPharma, Merck & Co., Inc., Mologen, Regeneron, Sanofi, Sumitomo Dainippon, Taiho Pharmaceutical, Vaccinogen

Regions Covered

North America, Europe, APAC, Latin America, MEA

Base Year

2021

Historical Year

2019 to 2020 (Data from 2010 can be provided as per availability)

Forecast Year

2030

Number of Pages

233

Number of Tables & Figures

164

Customization Available

Yes, the report can be customized as per your need.


Global Colorectal Cancer Drugs Industry Outlook


Global Colorectal Cancer Drugs Market Report Segments:

The global Colorectal Cancer Drugs market is segmented on the basis of:

Types

Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators,

The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.

Applications

Radiotherapy, Chemotherapy,

The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.

Some of the companies that are profiled in this report are:

  1. AB Science
  2. Amgen
  3. Array BioPharma
  4. Bayer
  5. Boehringer Ingelheim
  6. Bristol-Myers Squibb
  7. Elli Lilly
  8. Roch
  9. Hutchison MediPharma
  10. Merck & Co., Inc.
  11. Mologen
  12. Regeneron
  13. Sanofi
  14. Sumitomo Dainippon
  15. Taiho Pharmaceutical
  16. Vaccinogen

Global Colorectal Cancer Drugs Market Overview


Highlights of The Colorectal Cancer Drugs Market Report:

  1. The market structure and projections for the coming years.
  2. Drivers, restraints, opportunities, and current trends of market.
  3. Historical data and forecast.
  4. Estimations for the forecast period 2030.
  5. Developments and trends in the market.
  6. By Type:

    1. Vascular Endothelial Growth Factor (VEGF) Inhibitors
    2. Epidermal Growth Factor Receptor (EGFR) Inhibitors
    3. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
    4. BRAF or MEK Inhibitors
    5. Tyrosine Kinase (TKI) Inhibitors
    6. Immunomodulators
  1. By Application:

    1. Radiotherapy
    2. Chemotherapy
  1. Market scenario by region, sub-region, and country.
  2. Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
  3. Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
  4. Government Policies, Macro & Micro economic factors are also included in the report.

We have studied the Colorectal Cancer Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.

Regional Analysis

  • North America
  • Europe
  • Asia Pacific
  • Middle East & Africa
  • Latin America

Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.

The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.

How you may use our products:

  • Correctly Positioning New Products
  • Market Entry Strategies
  • Business Expansion Strategies
  • Consumer Insights
  • Understanding Competition Scenario
  • Product & Brand Management
  • Channel & Customer Management
  • Identifying Appropriate Advertising Appeals

Global Colorectal Cancer Drugs Market Statistics

8 Reasons to Buy This Report

  1. Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
  2. Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
  3. Implemented Robust Methodology to Prepare the Report
  4. Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
  5. Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
  6. Provides Information About the Top-winning Strategies Implemented by Industry Players.
  7. In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
  8. Customization of the Report Available

Frequently Asked Questions?


Colorectal cancer drugs are medications that can be used to treat colorectal cancer. These drugs can help to reduce the size of the tumor, improve the patient's overall health, and prolong their life.

Some of the key players operating in the colorectal cancer drugs market are AB Science, Amgen, Array BioPharma, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Elli Lilly, Roch, Hutchison MediPharma, Merck & Co., Inc., Mologen, Regeneron, Sanofi, Sumitomo Dainippon, Taiho Pharmaceutical, Vaccinogen.

                                            
1. Executive Summary

2. Assumptions and Acronyms Used

3. Research Methodology

4. Colorectal Cancer Drugs Market Overview
   4.1. Introduction
      4.1.1. Market Taxonomy
      4.1.2. Market Definition
   4.2. Macro-Economic Factors
      4.2.1. Industry Outlook
   4.3. Colorectal Cancer Drugs Market Dynamics
      4.3.1. Market Drivers
      4.3.2. Market Restraints
      4.3.3. Opportunity
      4.3.4. Market Trends
   4.4. Colorectal Cancer Drugs Market - Supply Chain
   4.5. Global Colorectal Cancer Drugs Market Forecast
      4.5.1. Colorectal Cancer Drugs Market Size (US$ Mn) and Y-o-Y Growth
      4.5.2. Colorectal Cancer Drugs Market Size (000’ Units) and Y-o-Y Growth
      4.5.3. Colorectal Cancer Drugs Market Absolute $ Opportunity

5. Global Colorectal Cancer Drugs Market Analysis and Forecast by Type
   5.1. Market Trends
   5.2. Introduction
      5.2.1. Basis Point Share (BPS) Analysis by Type
      5.2.2. Y-o-Y Growth Projections by Type
   5.3. Colorectal Cancer Drugs Market Size and Volume Forecast by Type
      5.3.1. Vascular Endothelial Growth Factor (VEGF) Inhibitors
      5.3.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors
      5.3.3. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
      5.3.4. BRAF or MEK Inhibitors
      5.3.5. Tyrosine Kinase (TKI) Inhibitors
      5.3.6. Immunomodulators
   5.4. Absolute $ Opportunity Assessment by Type
   5.5. Market Attractiveness/Growth Potential Analysis by Type

6. Global Colorectal Cancer Drugs Market Analysis and Forecast by Application
   6.1. Market Trends
   6.2. Introduction
      6.2.1. Basis Point Share (BPS) Analysis by Application
      6.2.2. Y-o-Y Growth Projections by Application
   6.3. Colorectal Cancer Drugs Market Size and Volume Forecast by Application
      6.3.1. Radiotherapy
      6.3.2. Chemotherapy
   6.4. Absolute $ Opportunity Assessment by Application
   6.5. Market Attractiveness/Growth Potential Analysis by Application

7. Global Colorectal Cancer Drugs Market Analysis and Forecast by Sales Channel
   7.1. Market Trends
   7.2. Introduction
      7.2.1. Basis Point Share (BPS) Analysis by Sales Channel 
      7.2.2. Y-o-Y Growth Projections by Sales Channel
   7.3. Colorectal Cancer Drugs Market Size and Volume Forecast by Sales Channel 
      7.3.1. Manufacturer/Distributor/Service Provider
      7.3.2. Aftermarket
   7.4. Absolute $ Opportunity Assessment by Sales Channel
   7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel

8. Global Colorectal Cancer Drugs Market Analysis and Forecast by Region
   8.1. Market Trends
   8.2. Introduction
      8.2.1. Basis Point Share (BPS) Analysis by Region
      8.2.2. Y-o-Y Growth Projections by Region
   8.3. Colorectal Cancer Drugs Market Size and Volume Forecast by Region
      8.3.1. North America
      8.3.2. Latin America
      8.3.3. Europe
      8.3.4. Asia Pacific
      8.3.5. Middle East and Africa (MEA)
   8.4. Absolute $ Opportunity Assessment by Region
   8.5. Market Attractiveness/Growth Potential Analysis by Region
   8.6. Global Colorectal Cancer Drugs Demand Share Forecast, 2019-2026

9. North America Colorectal Cancer Drugs Market Analysis and Forecast
   9.1. Introduction
      9.1.1. Basis Point Share (BPS) Analysis by Country
      9.1.2. Y-o-Y Growth Projections by Country
   9.2. North America Colorectal Cancer Drugs Market Size and Volume Forecast by Country
      9.2.1. U.S.
      9.2.2. Canada
   9.3. Absolute $ Opportunity Assessment by Country
   9.4. North America Colorectal Cancer Drugs Market Size and Volume Forecast by Application
      9.4.1. Radiotherapy
      9.4.2. Chemotherapy
   9.5. Basis Point Share (BPS) Analysis by Application
   9.6. Y-o-Y Growth Projections by Application
   9.7. North America Colorectal Cancer Drugs Market Size and Volume Forecast by Type
      9.7.1. Vascular Endothelial Growth Factor (VEGF) Inhibitors
      9.7.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors
      9.7.3. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
      9.7.4. BRAF or MEK Inhibitors
      9.7.5. Tyrosine Kinase (TKI) Inhibitors
      9.7.6. Immunomodulators
   9.8. Basis Point Share (BPS) Analysis by Type
   9.9. Y-o-Y Growth Projections by Type
   9.10. Market Attractiveness/Growth Potential Analysis
      9.10.1. By Country
      9.10.2. By Product Type
      9.10.3. By Application
      9.10.4. By Sales Channel
   9.11. North America Colorectal Cancer Drugs Demand Share Forecast, 2019-2026

10. Latin America Colorectal Cancer Drugs Market Analysis and Forecast
   10.1. Introduction
      10.1.1. Basis Point Share (BPS) Analysis by Country
      10.1.2. Y-o-Y Growth Projections by Country
      10.1.3. Latin America Average Pricing Analysis
   10.2. Latin America Colorectal Cancer Drugs Market Size and Volume Forecast by Country
      10.2.1. Brazil
      10.2.2. Mexico
      10.2.3. Rest of Latin America
   10.3. Absolute $ Opportunity Assessment by Country
   10.4. Latin America Colorectal Cancer Drugs Market Size and Volume Forecast by Application
      10.4.1. Radiotherapy
      10.4.2. Chemotherapy
    10.5. Basis Point Share (BPS) Analysis by Application
   10.6. Y-o-Y Growth Projections by Application
   10.7. Latin America Colorectal Cancer Drugs Market Size and Volume Forecast by Type
      10.7.1. Vascular Endothelial Growth Factor (VEGF) Inhibitors
      10.7.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors
      10.7.3. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
      10.7.4. BRAF or MEK Inhibitors
      10.7.5. Tyrosine Kinase (TKI) Inhibitors
      10.7.6. Immunomodulators
    10.8. Basis Point Share (BPS) Analysis by Type
   10.9. Y-o-Y Growth Projections by Type
   10.10. Market Attractiveness/Growth Potential Analysis
      10.10.1. By Country
      10.10.2. By Product Type
      10.10.3. By Application
      10.10.4. By Sales Channel
   10.11. Latin America Colorectal Cancer Drugs Demand Share Forecast, 2019-2026

11. Europe Colorectal Cancer Drugs Market Analysis and Forecast
   11.1. Introduction
      11.1.1. Basis Point Share (BPS) Analysis by Country
      11.1.2. Y-o-Y Growth Projections by Country
      11.1.3. Europe Average Pricing Analysis
   11.2. Europe Colorectal Cancer Drugs Market Size and Volume Forecast by Country
      11.2.1. Germany
      11.2.2. France
      11.2.3. Italy
      11.2.4. U.K.
      11.2.5. Spain
      11.2.6. Russia
      11.2.7. Rest of Europe
   11.3. Absolute $ Opportunity Assessment by Country
   11.4. Europe Colorectal Cancer Drugs Market Size and Volume Forecast by Application
      11.4.1. Radiotherapy
      11.4.2. Chemotherapy
    11.5. Basis Point Share (BPS) Analysis by Application
   11.6. Y-o-Y Growth Projections by Application
   11.7. Europe Colorectal Cancer Drugs Market Size and Volume Forecast by Type
      11.7.1. Vascular Endothelial Growth Factor (VEGF) Inhibitors
      11.7.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors
      11.7.3. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
      11.7.4. BRAF or MEK Inhibitors
      11.7.5. Tyrosine Kinase (TKI) Inhibitors
      11.7.6. Immunomodulators
    11.8. Basis Point Share (BPS) Analysis by Type
   11.9. Y-o-Y Growth Projections by Type
   11.10. Market Attractiveness/Growth Potential Analysis
      11.10.1. By Country
      11.10.2. By Product Type
      11.10.3. By Application
      11.10.4. By Sales Channel
   11.11. Europe Colorectal Cancer Drugs Demand Share, 2019-2026

12. Asia Pacific Colorectal Cancer Drugs Market Analysis and Forecast
   12.1. Introduction
      12.1.1. Basis Point Share (BPS) Analysis by Country
      12.1.2. Y-o-Y Growth Projections by Country
      12.1.3. Asia Pacific Average Pricing Analysis
   12.2. Asia Pacific Colorectal Cancer Drugs Market Size and Volume Forecast by Country
      12.2.1. China
      12.2.2. Japan
      12.2.3. South Korea
      12.2.4. India
      12.2.5. Australia
      12.2.6. Rest of Asia Pacific (APAC)
   12.3. Absolute $ Opportunity Assessment by Country
   12.4. Asia Pacific Colorectal Cancer Drugs Market Size and Volume Forecast by Application
      12.4.1. Radiotherapy
      12.4.2. Chemotherapy
    12.5. Basis Point Share (BPS) Analysis by Application
   12.6. Y-o-Y Growth Projections by Application
   12.7. Asia Pacific Colorectal Cancer Drugs Market Size and Volume Forecast by Type
      12.7.1. Vascular Endothelial Growth Factor (VEGF) Inhibitors
      12.7.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors
      12.7.3. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
      12.7.4. BRAF or MEK Inhibitors
      12.7.5. Tyrosine Kinase (TKI) Inhibitors
      12.7.6. Immunomodulators
    12.8. Basis Point Share (BPS) Analysis by Type
   12.9. Y-o-Y Growth Projections by Type
   12.10. Market Attractiveness/Growth Potential Analysis
      12.10.1. By Country
      12.10.2. By Product Type
      12.10.3. By Application
      12.10.4. By Sales Channel
   12.11. Asia Pacific Colorectal Cancer Drugs Demand Share, 2019-2026

13. Middle East & Africa Colorectal Cancer Drugs Market Analysis and Forecast
   13.1. Introduction
      13.1.1. Basis Point Share (BPS) Analysis by Country
      13.1.2. Y-o-Y Growth Projections by Country
      13.1.3. Asia Pacific Average Pricing Analysis
   13.2. Middle East & Africa Colorectal Cancer Drugs Market Size and Volume Forecast by Country
      13.2.1. Saudi Arabia
      13.2.2. South Africa
      13.2.3. UAE
      13.2.4. Rest of Middle East & Africa (MEA)
   13.3. Absolute $ Opportunity Assessment by Country
   13.4. Middle East & Africa Colorectal Cancer Drugs Market Size and Volume Forecast by Application
      13.4.1. Radiotherapy
      13.4.2. Chemotherapy
    13.5. Basis Point Share (BPS) Analysis by Application
   13.6. Y-o-Y Growth Projections by Application
   13.7. Middle East & Africa Colorectal Cancer Drugs Market Size and Volume Forecast by Type
      13.7.1. Vascular Endothelial Growth Factor (VEGF) Inhibitors
      13.7.2. Epidermal Growth Factor Receptor (EGFR) Inhibitors
      13.7.3. Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors
      13.7.4. BRAF or MEK Inhibitors
      13.7.5. Tyrosine Kinase (TKI) Inhibitors
      13.7.6. Immunomodulators
    13.8. Basis Point Share (BPS) Analysis by Type
   13.9. Y-o-Y Growth Projections by Type
   13.10. Market Attractiveness/Growth Potential Analysis
      13.10.1. By Country
      13.10.2. By Product Type
      13.10.3. By Application
      13.10.4. By Sales Channel
   13.11. Middle East & Africa Colorectal Cancer Drugs Demand Share, 2019-2026

14. Competition Landscape
   14.1. Global Colorectal Cancer Drugs Market: Market Share Analysis
   14.2. Colorectal Cancer Drugs Distributors and Customers
   14.3. Colorectal Cancer Drugs Market: Competitive Dashboard
   14.4. Company Profiles (Details – Overview, Financials, Developments, Strategy) 
      14.4.1. AB Science
         14.4.1.1. Overview
         14.4.1.2. Financials
         14.4.1.3. Developments
         14.4.1.4. Strategic Outlook
      14.4.2. Amgen
         14.4.2.1. Overview
         14.4.2.2. Financials
         14.4.2.3. Developments
         14.4.2.4. Strategic Outlook
      14.4.3. Array BioPharma
         14.4.3.1. Overview
         14.4.3.2. Financials
         14.4.3.3. Developments
         14.4.3.4. Strategic Outlook
      14.4.4. Bayer
         14.4.4.1. Overview
         14.4.4.2. Financials
         14.4.4.3. Developments
         14.4.4.4. Strategic Outlook
      14.4.5. Boehringer Ingelheim
         14.4.5.1. Overview
         14.4.5.2. Financials
         14.4.5.3. Developments
         14.4.5.4. Strategic Outlook
      14.4.6. Bristol-Myers Squibb
         14.4.6.1. Overview
         14.4.6.2. Financials
         14.4.6.3. Developments
         14.4.6.4. Strategic Outlook
      14.4.7. Elli Lilly
         14.4.7.1. Overview
         14.4.7.2. Financials
         14.4.7.3. Developments
         14.4.7.4. Strategic Outlook
      14.4.8. Roch
         14.4.8.1. Overview
         14.4.8.2. Financials
         14.4.8.3. Developments
         14.4.8.4. Strategic Outlook
      14.4.9. Hutchison MediPharma
         14.4.9.1. Overview
         14.4.9.2. Financials
         14.4.9.3. Developments
         14.4.9.4. Strategic Outlook
      14.4.10. Merck & Co., Inc.
         14.4.10.1. Overview
         14.4.10.2. Financials
         14.4.10.3. Developments
         14.4.10.4. Strategic Outlook
      14.4.11. Mologen
         14.4.11.1. Overview
         14.4.11.2. Financials
         14.4.11.3. Developments
         14.4.11.4. Strategic Outlook
      14.4.12. Regeneron
         14.4.12.1. Overview
         14.4.12.2. Financials
         14.4.12.3. Developments
         14.4.12.4. Strategic Outlook
      14.4.13. Sanofi
         14.4.13.1. Overview
         14.4.13.2. Financials
         14.4.13.3. Developments
         14.4.13.4. Strategic Outlook
      14.4.14. Sumitomo Dainippon
         14.4.14.1. Overview
         14.4.14.2. Financials
         14.4.14.3. Developments
         14.4.14.4. Strategic Outlook
      14.4.15. Taiho Pharmaceutical
         14.4.15.1. Overview
         14.4.15.2. Financials
         14.4.15.3. Developments
         14.4.15.4. Strategic Outlook
      14.4.16. Vaccinogen
         14.4.16.1. Overview
         14.4.16.2. Financials
         14.4.16.3. Developments
         14.4.16.4. Strategic Outlook
      14.4.17. COMPANY 17
         14.4.17.1. Overview
         14.4.17.2. Financials
         14.4.17.3. Developments
         14.4.17.4. Strategic Outlook
      14.4.18. COMPANY 18
         14.4.18.1. Overview
         14.4.18.2. Financials
         14.4.18.3. Developments
         14.4.18.4. Strategic Outlook
      14.4.19. COMPANY 19
         14.4.19.1. Overview
         14.4.19.2. Financials
         14.4.19.3. Developments
         14.4.19.4. Strategic Outlook
      14.4.20. COMPANY 20
         14.4.20.1. Overview
         14.4.20.2. Financials
         14.4.20.3. Developments
         14.4.20.4. Strategic Outlook

Our Trusted Clients

Contact Us